ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

antihemophilic factor, human recombinant

Also written as “Antihemophilic factor, recombinant, manufactured protein-free”, “Recombinant Factor VIII (BAY81-8973)” and “ADVATE”.

Its studies are mostly in Hemophilia A · von Willebrand Diseases, led by 3 companies.

Drug pageAntihemophilic factor, human recombinant: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 21, 200516 company-led studies, 1 open or runningNext primary completion: Nov 25, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda101 open or runningphase 4since Oct 21, 2005Sep 8, 2005Nov 25, 2027phase 3 · NCT07129343
Bayerits history only50 open or runningphase 4since Sep 4, 2020Dec 8, 2009none ahead
Novo Nordiskits history only10 open or runningphase 1since Feb 4, 2009Feb 4, 2009none ahead

Also a collaborator on its studies: Takeda Development Center Americas and Baxter Innovations.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Takeda only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 8, 2005First studies: 3 phase 3 studies in Hemophilia AFirst studyNCT00157105, NCT00157053, NCT00157040
  2. Oct 21, 2005Phase 4 study in Hemophilia ANCT00243386 · 82 enrolled · United States, Austria, Czechia and more
  3. Feb 9, 2006Phase 4 study in Hemophilia ANCT00289536 · 38 enrolled · United States
  4. Aug 4, 2009Phase 1 study in Hemophilia ANCT00952822 · 52 enrolled · United States
  5. Jun 17, 2011Phase 3 study in Hemophilia ANCT01376700 · 22 enrolled · United States, Austria, Bulgaria and more
  6. Oct 12, 2016Phase 3 study in von Willebrand DiseasesNCT02932618 · 47 enrolled · United States, Austria, Belgium and more
  7. Jul 29, 2021Phase 4 study in Hemophilia ANCT04985682 · 50 enrolled · India
  8. Aug 12, 2025Phase 3 study in von Willebrand DiseasesNCT07129343 · 20 planned · China

Ahead

  1. Nov 25, 2027Primary completion: phase 3 study in von Willebrand DiseasesNCT07129343

TargetBeta

F8 →read by rule
“Coagulation factor VIII exogenous protein”ChEMBL 37, by rule

Other programs on F8

ProgramCompanyFurthest phaseStudies
efanesoctocog alfaruleSanofiphase 412
omfiloctocog alfaruleSinocelltech Groupphase 46
lonoctocog alfaruleCSLphase 34

Studies

All 10 Takeda leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07129343von Willebrand Diseases · China3RecruitingNov 25, 202720
NCT04985682Hemophilia A · India4CompletedFeb 10, 202350
NCT02932618von Willebrand Diseases · United States, Austria, Belgium and more3CompletedApr 17, 202647
NCT01376700Hemophilia A · United States, Austria, Bulgaria and more3TerminatedNov 16, 201222
NCT00952822Hemophilia A · United States1CompletedOct 23, 200952
NCT00289536Hemophilia A · United States4CompletedApr 1, 200738
NCT00243386Hemophilia A · United States, Austria, Czechia and more4CompletedJun 16, 201082
NCT00157105Hemophilia A · United States3CompletedAug 3, 200459
NCT00157053Hemophilia A · United States, Austria, Belgium and more3CompletedAug 3, 200482
NCT00157040Hemophilia A · United States, Canada, Puerto Rico3CompletedJan 4, 200550

How it is read

Names in the registry

  • “Antihemophilic factor, recombinant, manufactured protein-free”, 8 entries
  • “Recombinant Factor VIII (BAY81-8973)”, 3 entries
  • “ADVATE”, 2 entries
  • “Recombinant Factor VIII (Kovaltry, BAY81-8973)”, 2 entries
  • “Antihemophilic Factor (Recombinant)”, 1 entry

Codes read as this program: BAY818973.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.